Medindia

X

Cambridge-Based Company Signs a $60 million Deal For a Drug With Mitsubishi Pharma

by Reshma Anand on  September 11, 2015 at 1:54 PM Corporate News   - G J E 4
Biogen to exclusively license MT-1303, a late stage experimental medicine with potential in multiple autoimmune indications, from Mitsubishi Tanabe Pharma Corporation (MTPC). MT-1303 is an oral compound that targets the sphingosine 1-phosphate (S1P) receptor.
Cambridge-Based Company Signs a $60 million Deal For a Drug With Mitsubishi Pharma
Cambridge-Based Company Signs a $60 million Deal For a Drug With Mitsubishi Pharma
Advertisement

Biogen is assessing the potential of MT-1303 in multiple sclerosis (MS), ulcerative colitis, Crohn's disease, and other autoimmune indications. The compound has completed a successful Phase 2 clinical trial in MS and Biogen is evaluating a rapid development program in this indication. The company will also investigate indications in inflammatory bowel disease. Biogen will initiate a clinical trial in ulcerative colitis and may advance an existing program in Crohn's disease to Phase 3.

Advertisement
"Based on compelling efficacy and safety data, we believe that MT-1303 could be a best-in-class S1P modulator. There is a great need for effective oral therapies for the treatment of inflammatory bowel disease and other autoimmune indications, and we are excited to strengthen our late-stage pipeline with this next-generation oral investigational therapy," said Alfred Sandrock, vice president and chief medical officer at Biogen.

Biogen will receive worldwide rights to MT-1303, excluding Asia. It will be responsible for global commercialization and also cover development costs outside of Asian territories. MTPC will receive an upfront payment of $60 million from Biogen and may receive up to $484 million in additional milestone payments for multiple indications and territories. MTPC has the right to participate in Biogen's global clinical trials and has an option to co-promote non-MS indications in the U.S.

The transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the United States, and is expected to close in the fourth calendar quarter of 2015.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All